Summary: In singleton pregnancies with gestational diabetes inadequately controlled after dietary therapy, a metformin-first oral strategy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth (23.9% vs 19.9%; absolute risk difference 4.0%, 95% CI -1.7% to 9.8%). Maternal hypoglycaemia was also more frequent with the oral-agent strategy.
PICO Summary
| Element | Detail |
|---|---|
| Population | 820 individuals with singleton pregnancies and gestational diabetes at 16-34 weeks after failed dietary therapy; multicentre, open-label noninferiority RCT in 25 Dutch centres. |
| Intervention | Metformin started at 500 mg daily and titrated to 1000 mg twice daily as tolerated (n=409), with glyburide added and later insulin substituted if targets were not met. |
| Comparison | Insulin according to local practice (n=411), with both groups targeting the same fasting and postprandial glucose thresholds. |
| Outcome | Large-for-gestational-age birth occurred in 23.9% with oral agents versus 19.9% with insulin (absolute risk difference 4.0%, 95% CI -1.7% to 9.8%; noninferiority not met). Maternal hypoglycaemia occurred in 20.9% versus 10.9%, respectively. |
Oral Agents vs Insulin for GDM
Open-label RCT - singleton GDM - 16-34 weeks
Metformin-first oral therapy with rescue glyburide did not prove noninferior to insulin for preventing large-for-gestational-age birth; maternal hypoglycaemia was more frequent.
Expert Commentary
This trial answers a practical question clinicians face every week: can a metformin-first strategy, with glyburide added before switching to insulin, replace insulin without worsening important perinatal outcomes? For the primary endpoint, the answer is no. The oral-agent strategy did not meet the prespecified noninferiority criterion for preventing large-for-gestational-age birth, so it should not be presented as equivalent to insulin when fetal overgrowth is the main concern. Maternal hypoglycaemia was also reported more often with oral therapy. The result still has nuance. Nearly four in five participants assigned to oral agents maintained glycaemic control without insulin, and most secondary neonatal outcomes were similar, so the study remains useful for counselling when insulin is unacceptable, delayed, or difficult to implement. The main limitation is design: the trial was open label, and the sequential use of glyburide complicates attribution to metformin alone. Can I use this with my patients? Yes, mainly to explain why insulin remains the standard medication after diet failure when reducing large-for-gestational-age birth is the priority. Oral agents can still be discussed selectively, but not as clearly noninferior substitutes. Longer child follow-up and cleaner metformin-only comparisons are still needed.
References
Rademaker D, de Wit L, Duijnhoven RG, et al. Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial. JAMA. 2025;333(6):470. doi:10.1001/jama.2024.23410. PMID: 39761054.